17-Hydroxylase deficiency is mistaken for essential hypertension, primary amenorrhea of unknown cause, and ‘constitutional delay’ all at once. A four-line lab panel resolves the entire picture.

A 17-year-old girl is referred for primary amenorrhea. Her blood pressure is 168/104. Her serum potassium is 2.9 mmol/L. The general practitioner has started amlodipine and ordered an FSH. Three of the four findings on this referral letter are pointing at the same enzyme, and none of them will be solved by an antihypertensive or a hormone profile alone.

#one_enzyme_three_phenotypes

17α-hydroxylase/17,20-lyase is a single cytochrome P450 enzyme (a family of liver and adrenal oxidative enzymes) encoded by the CYP17A1 gene (cytochrome P450 family 17 subfamily A member 1) on chromosome 10q24. It performs two sequential reactions in adrenal and gonadal steroid biosynthesis (the body’s production of cortisol, mineralocorticoids, and sex hormones): 17α-hydroxylation of pregnenolone and progesterone (producing the precursors of the stress hormone cortisol), and 17,20-lyase cleavage (producing the precursors of male androgens and female estrogens). A biallelic loss-of-function mutation — meaning both copies of the gene are defective — in CYP17A1 therefore eliminates two downstream classes of steroids simultaneously — glucocorticoids (cortisol-type hormones) and sex steroids — while leaving the mineralocorticoid pathway (the aldosterone branch that regulates sodium and blood pressure) not only intact but pathologically amplified.

The amplification is the source of the clinical signature. Adrenocorticotropic hormone (ACTH — the pituitary hormone that drives adrenal cortisol production) cannot be suppressed because cortisol output is low; chronically elevated ACTH drives unrestricted flow through the only steroidogenic branch that remains open — the mineralocorticoid arm — and forces the accumulation of 11-deoxycorticosterone (DOC, an aldosterone-like sodium-retaining hormone) and corticosterone (a related precursor with both glucocorticoid and mineralocorticoid activity). DOC is a potent mineralocorticoid in its own right — it activates the same receptor that aldosterone normally activates, causing sodium retention, potassium loss, and elevated blood pressure. The result is volume-expanded, low-renin hypertension (high blood pressure with suppressed renin, an enzyme that signals low blood volume) with hypokalemia (low blood potassium), identical in mechanism to a primary aldosteronism phenotype but without elevated aldosterone (which is itself suppressed by chronic volume expansion).

Sex steroid deficiency is the second consequence. In a 46,XX individual (chromosomal female, with two X chromosomes) it produces primary amenorrhea (failure to ever start menstruation), absent thelarche (no breast development), an infantile uterus, and multifollicular ovaries arrested before antral development (early-stage follicles that never mature into eggs ready for ovulation). In a 46,XY individual (chromosomal male, with one X and one Y chromosome) it produces female-appearing external genitalia (because androgen synthesis fails during the critical window for genital virilization in early fetal development), intra-abdominal or inguinal testes (testicles that never descended into the scrotum), and a phenotype almost always raised female from birth until adolescent presentation forces the karyotype (chromosomal analysis).

The disorder accounts for roughly 1% of congenital adrenal hyperplasia (CAH — a family of inherited disorders of steroid synthesis in which the adrenal glands cannot make enough cortisol) and an estimated incidence of 1 per 50,000 births, with founder-effect clusters (populations where a single ancestral mutation became locally common) in Brazil, China, Japan, and Türkiye. It is not detected on newborn screening, which targets the far commoner 21-hydroxylase form of CAH. The diagnostic age is typically 14–17, when delayed puberty forces evaluation.

#why_it_looks_like_essential_hypertension

The diagnostic delay in 17-hydroxylase deficiency (17-OHD — the standard abbreviation for the disorder) is driven by the disorder’s habit of presenting one element at a time. A 12-year-old with hypertension and hypokalemia is investigated for renal artery stenosis (narrowing of the kidney’s blood supply), primary aldosteronism (an aldosterone-producing adrenal tumor or hyperplasia), and licorice intake (real licorice contains glycyrrhizin, which mimics aldosterone) — and discharged when each comes back negative. A 16-year-old with primary amenorrhea is sent to a gynecologist who orders FSH and LH (follicle-stimulating hormone and luteinizing hormone — the two pituitary hormones that drive the ovaries and testes) and finds them elevated (hypergonadotropic hypogonadism — high signal from the pituitary because the gonads are not responding) and refers for karyotype, which returns 46,XX, at which point the workup often stops. The hypertension is treated by a different clinic with amlodipine (a calcium-channel blocker antihypertensive) and never linked to the amenorrhea.

The unifying lab — a basal steroid profile (a panel of steroid hormone measurements taken under normal, unstimulated conditions) — is rarely ordered because it requires the clinician to consider the steroidogenic pathway as a system rather than as a series of individual measurements. The pattern, once requested, is unmistakable: low cortisol with elevated ACTH, low aldosterone with suppressed renin, very high 11-deoxycorticosterone, high corticosterone, and absent or very low circulating androgens (male-pattern hormones, dominant being testosterone) and estrogens (female-pattern hormones, dominant being estradiol). The ACTH-stimulation test (an injection of synthetic ACTH followed by serial cortisol and steroid precursor measurements) sharpens the picture further by demonstrating a clamped response in the 17-hydroxylated steroids — those produced after the blocked enzyme step — (low or absent 17-OH-pregnenolone, 17-OH-progesterone, cortisol, DHEA — dehydroepiandrosterone, androstenedione) against an exuberant response in the non-17-hydroxylated steroids that bypass the block (DOC, corticosterone).

#the_46xy_problem

The most consequential diagnostic moment in 17-OHD is the karyotype (the laboratory analysis of an individual’s chromosomes) in a phenotypically female adolescent who presents with primary amenorrhea and absent breast development. Approximately 90% of 46,XY individuals with complete 17-OHD are raised female from birth, because the external genitalia (vulva, labia) are female-typical. The internal anatomy, however, is male: bilateral testes (usually intra-abdominal or inguinal — located inside the abdomen or in the groin canal rather than the scrotum), absent uterus, and a blind-ending vagina (a vaginal canal that does not connect to a uterus).

Two clinical decisions follow. First, the patient must be informed in age-appropriate language with psychological support, ideally by a clinician experienced in disorders of sex development (DSD — the modern umbrella term for conditions in which chromosomal, gonadal, or anatomical sex is atypical). Imposing this disclosure on the gynecologist who happens to be present in clinic is not acceptable practice; coordination with a multidisciplinary DSD service (a team that typically includes endocrinology, urology, psychology, and genetics) is the standard. Second, gonadectomy (surgical removal of the testes) is recommended because intra-abdominal testes carry an elevated lifetime risk of germ-cell malignancy (testicular cancers arising from the sperm-precursor cell line). The optimal timing is debated — historically performed in adolescence, increasingly delayed to allow patient participation in decision-making — but the indication is established.

Gender dysphoria (persistent distress about an assigned gender that does not match the individual’s experienced gender) in adults with 17-OHD is reported to be extremely rare, attributed to fetal androgen deficiency and consequent absence of prenatal androgen-driven brain masculinization (the hormonal shaping of brain development that normally occurs in male fetuses), but the rarity should not be used to override an individual patient’s choice. The clinical task is to present the diagnosis, the karyotype, and the management options without forcing a binary outcome.

#what_to_actually_measure

The lab panel that resolves the entire phenotype in a single morning blood draw:

• ACTH (08:00). Markedly elevated (often > 100 pg/mL).
• Cortisol (08:00). Low or undetectable at baseline; minimal rise on 250 µg cosyntropin stimulation.
• 11-deoxycorticosterone (DOC). Markedly elevated. The single most informative value.
• Corticosterone. Elevated; partially compensates for cortisol deficiency and explains the rarity of adrenal crisis.
• Aldosterone. Low or suppressed.
• Plasma renin activity. Suppressed (volume-expanded state).
• 17-OH-progesterone (17-hydroxyprogesterone, 17-OHP — the steroid intermediate immediately upstream of cortisol). Low or normal in 17-OHD (distinguishes it from 21-hydroxylase deficiency, the commoner CAH form, in which 17-OHP is dramatically elevated).
• Androstenedione, DHEA-S (dehydroepiandrosterone sulfate — the predominant circulating adrenal androgen), testosterone, estradiol. All low or absent.
• Gonadotropins: FSH and LH. Elevated (hypergonadotropic hypogonadism — the pituitary signals loudly because the gonads are silent).
• Karyotype. Mandatory in every case of primary amenorrhea with absent secondary sexual development.
• Pelvic ultrasound or MRI (magnetic resonance imaging — a non-ionizing cross-sectional imaging modality). To document internal genitalia and gonad location.
• CYP17A1 sequencing. Confirmatory genetic test; identifies the specific mutation among the more than 150 documented variants and informs family counselling (the assessment of inherited risk for siblings and future children).

The panel is unusual in that the diagnosis is established by what is absent (17-hydroxylated steroids) as much as by what is elevated (DOC, corticosterone, ACTH).

#treatment_the_two_targets

Management addresses both ends of the failed pathway. Neither alone is sufficient.

Glucocorticoid replacement

Physiological hydrocortisone (the pharmaceutical form of natural cortisol) at 10–15 mg/m² per day in divided doses replaces cortisol and, by suppressing ACTH, removes the drive for mineralocorticoid precursor overproduction. Within weeks the DOC concentration falls, volume expansion resolves, and blood pressure and potassium normalize without dedicated antihypertensive therapy in many patients. Dexamethasone (a long-acting synthetic glucocorticoid) is sometimes substituted in adults for its more reliable ACTH suppression at the cost of higher Cushingoid risk (iatrogenic features of glucocorticoid excess: central obesity, thin skin, easy bruising, hypertension); the standard recommendation remains hydrocortisone as the most physiological agent. Stress-dose protocols (double or triple usual dose during febrile illness, surgery, or major injury — needed because cortisol output normally rises sharply with stress and the replaced patient cannot do this physiologically) are mandatory and must be taught to the patient and family at diagnosis.

Sex steroid replacement

Estrogen replacement is initiated in 46,XX and 46,XY-raised-female patients in adolescence, beginning with low-dose transdermal estradiol (an estrogen skin patch) and progressing to cyclic estrogen–progestin therapy (estrogen plus a synthetic progesterone in a monthly cycle that mimics the natural menstrual hormone pattern) once breakthrough bleeding indicates uterine readiness. Progestin is mandatory in patients with a uterus to prevent endometrial hyperplasia (overgrowth of the uterine lining that can progress to cancer when estrogen is unopposed by progesterone). In 46,XY-raised-male patients (rare in 17-OHD, more common in partial enzyme defects), testosterone replacement is initiated according to standard hypogonadism protocols. Pubertal induction is gradual — over 18 to 24 months — to allow physiological breast and growth trajectories and to avoid the psychological dissonance of rapid pubertal change.

Residual hypertension

A subset of patients remain hypertensive despite adequate glucocorticoid replacement because of long-standing vascular remodelling (structural stiffening of arteries from chronic high pressure) or incomplete ACTH suppression. Spironolactone (25–100 mg/day) or eplerenone is first-line — both are mineralocorticoid receptor antagonists that block the receptor DOC over-activated for years. Standard antihypertensive classes are added as needed but should not substitute for the underlying glucocorticoid replacement.

Fertility

Infertility is the rule in untreated disease but is no longer the rule in treated disease. Recent protocols using progesterone-primed ovarian stimulation (a fertility-treatment regimen designed for patients with abnormally high baseline progesterone, common in 17-OHD), dexamethasone co-treatment to suppress endogenous progesterone, and assisted reproductive technology (including in-vitro fertilization, abbreviated IVF) have produced increasing numbers of live births in 46,XX women with 17-OHD. The 2024 meta-analysis by Du and colleagues documents the contemporary outcome distribution and should be cited in any patient discussion of fertility planning.

#when_the_diagnosis_is_almost_17ohd_but_isnt

Several conditions produce overlapping clinical pictures and must be excluded before settling the diagnosis:

• 11β-hydroxylase deficiency. Also a CAH variant with hypertension and hypokalemia, but with elevated androgens (virilization — appearance of male-type features such as facial hair, deep voice, and clitoromegaly — in 46,XX females, accelerated growth in both sexes). 11-deoxycortisol (the intermediate immediately upstream of the 11β-hydroxylase enzyme block) is markedly elevated; the molecular target is CYP11B1.
• Primary aldosteronism. Hypertension and hypokalemia with elevated aldosterone and suppressed renin. The aldosterone-to-renin ratio (ARR — the screening test in which elevated aldosterone and suppressed renin together produce a high ratio) is the entry test. 17-OHD has the opposite pattern: low aldosterone, suppressed renin.
• Apparent mineralocorticoid excess (AME). Defect in 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2 — the kidney enzyme that normally inactivates cortisol so it cannot activate the mineralocorticoid receptor) allowing cortisol to activate the mineralocorticoid receptor. Diagnosed by elevated urinary cortisol-to-cortisone ratio. Glucocorticoids and sex steroids are intact.
• Liddle syndrome. Autosomal dominant inherited disorder; gain-of-function mutation in the epithelial sodium channel of the kidney (ENaC) causes inappropriate sodium retention. Suppressed aldosterone and renin, normal steroid panel. Family history typical.
• Licorice or carbenoxolone ingestion. Pharmacological inhibition of 11β-HSD2 (the enzyme above); reversible on withdrawal. Always ask about chewing tobacco, herbal teas, ‘natural’ candies, and topical preparations.
• Turner syndrome and complete androgen insensitivity syndrome (CAIS). Both cause primary amenorrhea but produce distinct karyotypes, sex steroid profiles, and physical findings (short stature and webbed neck in Turner syndrome — karyotype 45,X with one missing or structurally abnormal X chromosome; normal female external phenotype with absent uterus and normal-to-elevated testosterone in CAIS — karyotype 46,XY with non-functioning androgen receptors).

#principle

When high blood pressure, low potassium, and absent puberty appear in the same adolescent, the question is not which specialist to refer to. The question is whether a single morning steroid profile has been drawn. ACTH (adrenocorticotropic hormone), cortisol, 11-deoxycorticosterone (DOC), aldosterone, renin, and the gonadotropin–sex-steroid pair (FSH/LH together with testosterone and estradiol), together with a karyotype, will identify or exclude 17-hydroxylase deficiency in a single visit. Treating each finding as a separate problem keeps the diagnosis hidden — typically for years.

Mineralocorticoid excess plus sex steroid deficiency is not an unusual coincidence. It is a single enzyme.

#sources

• Auchus RJ. Steroid 17-hydroxylase and 17,20-lyase deficiencies, genetic and pharmacologic. J Steroid Biochem Mol Biol. 2017;165(Pt A):71–78. PMID 27068427
• Kater CE, Biglieri EG. Disorders of steroid 17α-hydroxylase deficiency. Endocrinol Metab Clin North Am. 1994;23(2):341–357. PMID 8070425
• Siklar Z, et al. 17α-hydroxylase/17,20-lyase deficiency: clinical and molecular characterization. J Clin Res Pediatr Endocrinol. 2024. PMID 39020240
• Maheshwari M, et al. 17α-hydroxylase/17,20-lyase deficiency in 46,XY: phenotypic spectrum and management. Endocrine. 2022. PMID 35178494
• Du Q, Jia X, et al. 17α-Hydroxylase/17,20-lyase deficiency (17-OHD): a meta-analysis of reported cases. J Clin Endocrinol Metab. 2024;110(4):e1261–e1273. PMID 38776749
• Speiser PW, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(11):4043–4088. PMID 30272171

#about_the_author

Dr. Vladimir Pereligyn — endocrinologist, researcher, founder of universum.earth. Functional and preventive medicine with focus on thyroid, metabolic, adrenal, and reproductive endocrinology. Online consultations and personalized protocols: universum.earth/consultation. Instagram: @md_pereligyn_eng (English) and @md_pereligyn_thyroid (thyroid-focused, Russian). Patient-facing iOS companion app for thyroid, metabolic, and lab tracking: Teremok on the App Store.

This article is for informational and educational purposes and does not constitute medical advice. Patients with suspected congenital adrenal hyperplasia should be evaluated by an endocrinologist; specific diagnostic and therapeutic decisions must be individualized.

🌀Hypertension, Low Potassium, and No Puberty — The Single Genetic Block That Ties Them Together